Atorvastatin cuts anthracycline heart failure

Published Date: 08 Mar 2023

Atorvastatin 40 mg daily for 12 months reduces cardiovascular events in lymphoma patients treated with anthracyclines.

Read Full News

Latest News

Special Report: Reframing Skin Pain in Atopic Dermatitis Mona Shahriari, MD, FAAD, Andrew Mastro, MS, PA-C

This video explores skin pain as a key symptom of atopic dermatitis and reviews clinical trial data with JAK inhibitors.

Skin of Color Savvy: Winter Skin Care for Patients of Color, With Heather Woolery-Lloyd, MD, and Aderonke Obayomi, MD, MPH

Skin of Color Savvy: Winter Skin Care for Patients of Color, With Heather Woolery-Lloyd, MD, and Aderonke Obayomi, MD, MPH

Addictive Behaviors Linked with Chronic Skin Diseases Such as HS, Psoriasis

Addictive Behaviors Linked with Chronic Skin Diseases Such as HS, Psoriasis

Prurigo Nodularis Linked to Increased Risk of Malignancy, Especially Skin Cancers

Prurigo Nodularis Linked to Increased Risk of Malignancy, Especially Skin Cancers

Imsidolimab’s Biologics License Application for Treatment of GPP Submitted to FDA

Imsidolimab’s Biologics License Application for Treatment of GPP Submitted to FDA

Dupilumab Shows Greatest Rate of 2-Year Drug Survival Among Atopic Dermatitis Drugs

Dupilumab Shows Greatest Rate of 2-Year Drug Survival Among Atopic Dermatitis Drugs

Todays Updates

2024 Primary Stroke Prevention Guidelines: Key Takeaways and Clinical Implications Walter Kernan, MD, Isabella Ciccone, MPH

Walter Kernan, MD, senior research scientist at Yale University, discussed the latest primary stroke prevention guidelines and their focus on lifelong brain health and risk factor management.

A Clinical Review of the 2025 Restless Leg Syndrome Guidelines Louie Pasculli, Andy Berkowski, MD, PhD

Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

IgA Nephropathy Prediction Model Aids 5-Year Survival Estimation

IgA Nephropathy Prediction Model Aids 5-Year Survival Estimation

Increased Physical Activity Linked to Reduced Mortality In Peritoneal Dialysis

Increased Physical Activity Linked to Reduced Mortality In Peritoneal Dialysis

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

Todays Updates

2024 Primary Stroke Prevention Guidelines: Key Takeaways and Clinical Implications Walter Kernan, MD, Isabella Ciccone, MPH

Walter Kernan, MD, senior research scientist at Yale University, discussed the latest primary stroke prevention guidelines and their focus on lifelong brain health and risk factor management.

A Clinical Review of the 2025 Restless Leg Syndrome Guidelines Louie Pasculli, Andy Berkowski, MD, PhD

Andy Berkowski, MD, PhD, certified sleep neurologist and author of the RLS guidelines, spoke about the clinical impact of the recently published restless syndrome guidelines.

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

FDA Approves Depemokimab-ulaa (Exdensur) for Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

Sleep Disorders Linked to Poorer Symptom Control in Severe Asthma

IgA Nephropathy Prediction Model Aids 5-Year Survival Estimation

IgA Nephropathy Prediction Model Aids 5-Year Survival Estimation

Increased Physical Activity Linked to Reduced Mortality In Peritoneal Dialysis

Increased Physical Activity Linked to Reduced Mortality In Peritoneal Dialysis

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

GLP-1 RA Use Linked to 42% Hepatocellular Carcinoma Risk Reduction in T2DM

Latest News

This video explores skin pain as a key symptom of atopic dermatitis and reviews clinical trial data with JAK inhibitors.

Skin of Color Savvy: Winter Skin Care for Patients of Color, With Heather Woolery-Lloyd, MD, and Aderonke Obayomi, MD, MPH

Addictive Behaviors Linked with Chronic Skin Diseases Such as HS, Psoriasis

Prurigo Nodularis Linked to Increased Risk of Malignancy, Especially Skin Cancers

Imsidolimab’s Biologics License Application for Treatment of GPP Submitted to FDA

Dupilumab Shows Greatest Rate of 2-Year Drug Survival Among Atopic Dermatitis Drugs

News All Time

Topical Roflumilast 0.3% Effective, Safe in Systematic Review of Psoriasis Data

Topical Roflumilast 0.3% Effective, Safe in Systematic Review of Psoriasis Data

More Costly, Polarized Dermatoscope Results Compared to Nonpolarized Dermatoscope

More Costly, Polarized Dermatoscope Results Compared to Nonpolarized Dermatoscope

Session on the Skin Microbiome and Atopic Dermatitis Presented at 2025 SDPA Fall Conference

Session on the Skin Microbiome and Atopic Dermatitis Presented at 2025 SDPA Fall Conference

Difficult Cases and Red Flags in Dermatology, With Kassandra Holzem, MD Kassandra Holzem, MD

In her SDPA Fall Dermatology Conference interview, Holzem highlights key warning signs for a variety of dermatologic conditions requiring hospital admission.

8 Dermatology Headlines You Missed in November 2025

8 Dermatology Headlines You Missed in November 2025

Antibiotic Exposure Linked to Increased Risk of Biologic Discontinuation in Psoriasis

Antibiotic Exposure Linked to Increased Risk of Biologic Discontinuation in Psoriasis

sNDA for Ameluz-PDT as a Treatment for Superficial Basal Cell Carcinoma Submitted to FDA

sNDA for Ameluz-PDT as a Treatment for Superficial Basal Cell Carcinoma Submitted to FDA

INF904 Shows Strong Phase 2a Results in HS and CSU, With No Safety Signals

INF904 Shows Strong Phase 2a Results in HS and CSU, With No Safety Signals

Long-Term Course of HS Disease More Favorable Than Previous Estimates

Long-Term Course of HS Disease More Favorable Than Previous Estimates

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

Psoriasis Incidence Projected to Increase by 2025 Across Various Groups

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

Expert Consensus Provides Recommendations on Dermoscopy Standards for PAs

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

How to Recognize and Treat Atopic Dermatitis in Patients with Skin of Color

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Lebrikizumab Effectively Treats AD in Patients with Skin of Color, With Vinay Mehta, MD Vinay Mehta, MD

A phase 3b study in patients with skin of color found lebrikizumab provides reliable efficacy and safety for treating moderate-to-severe AD.

Lebrikizumab Benefits AD Patients With Skin of Color, With Vinay Mehta, MD Vinay Mehta, MD

New ACAAI 2025 data show lebrikizumab improves disease control, quality of life, and work productivity in patients of skin of color with moderate to severe atopic dermatitis.

Discussing New Topical Drugs for Atopic Dermatitis in Younger Patients, With Peter Lio, MD Peter Lio, MD

This Fall Clinical Dermatology Conference interview features Peter Lio, MD, discussing takeaways from several of his sessions at the meeting.

Recommended News For You

No Laughing Matter: Nitrous Oxide for Transrectal Prostate Biopsy.

Specific suicidal patterns mark the highest risk.

Congress Ditched Fix to Medicare Doc Pay Cut in Skinny Budget Bill

New study reveals racial disparities in breast cancer diagnosis and outcomes in Canada

Alone for 500 Days, but Never Lonely: The Introvert's Dream.

Transplantation Fails to Improve Survival in Mantle Cell Lymphoma

Breast Cancer Incidence Increased Due to Particulate Air Pollution, According to NIH Study.

Recommended Articles For You

Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment 

Cutting-Edge Cancer Treatments: Innovations and Outcomes in Non-Hodgkin Lymphoma 

Unlocking the Potential of Elotuzumab: A Promising New Cancer Treatment 

Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer

2.

Taking Charge of Your Cancer Journey.

3.

Depression risk higher among long-term breast cancer survivors than women without breast cancer history

4.

Small Renal Mass Surveillance Does Not Affect Nephron-Sparing Surgery.

5.

UK government can save lives and smash inequalities by changing prostate cancer guidelines, say experts

1.

AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies

2.

All You Need to Know About Mesna: The Ultimate Guide

3.

Understanding the Importance of Red Cell Distribution Width (RDW) in Blood Tests 

4.

Future of Oncology: Targeted Therapies & Collaborative Innovation Shaping Cancer Care in the USA

5.

Neuroendocrine Tumors: Case Study on Diagnosis, Treatment Strategies & Patient Management

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity

2.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II

3.

From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2

4.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI

5.

Navigating the Complexities of Ph Negative ALL - Part XVI

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot